Headache News and Research

Latest Headache News and Research

Antibody levels against SARS-CoV-2 spike protein up to 12 months after COVID-19 infection in non-vaccinated individuals

A recent study assessed the persistence of SARS-CoV-2 antibody five and 12 months post-infection in non-vaccinated patients.

24 Feb 2022

Closing bars and restaurants does not appear to have suppressed COVID-19 in Japan

In a recent study posted in the Research Square* preprint server, which is under consideration at the journal Scientific Reports, a team of researchers conducted a longitudinal survey in 11 Japanese prefectures to evaluate whether early closure of full-service restaurants and bars reduced the incidence and symptoms of coronavirus disease 2019 (COVID-19) during February 2021.

23 Feb 2022

Prevalence of chemosensory loss induced by SARS-CoV-2 Omicron variant in Italy

Researchers conducted a prospective cohort study to determine the prevalence of chemosensory dysfunction in mild to moderate COVID-19 patients in Italy.

22 Feb 2022

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

In a new study, researchers evaluated the efficacy and safety of nirmatrelvir in mild to moderate COVID-19 patients who were at high risk of severe COVID-19 disease.

18 Feb 2022

Immunogenicity, efficacy, and safety of BNT162b2 or mRNA1273 fourth dose

A recent study explored the safety, immunogenicity, and VE of the SARS-CoV-2 mRNA BNT162b2 and mRNA1273 vaccines against its Omicron VOC in HCWs in Israel.

18 Feb 2022

Study determines 115 long COVID symptoms and their associated risk factors

A new study determined which symptoms are linked with confirmed SARS-CoV-2 infection beyond 12 weeks post-infection in non-hospitalized individuals, and investigated the associated risk-factors of such symptoms.

17 Feb 2022

Risk factors for COVID-19 in older adult patients with cancer

Researchers develop a geriatric risk score to predict the risk of severe clinical outcomes in older cancer patients with COVID-19.

16 Feb 2022

UC joins nationwide trial to evaluate efficacy of repurposed drugs for mild-to-moderate COVID-19

The University of Cincinnati is joining a nationwide study to evaluate repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19. Repurposed medications are those already approved by the U.S. Food and Drug Administration for other indications.

16 Feb 2022

Pregnancy outcomes of pregnant women infected by SARS-CoV-2

A new study evaluated the pregnancy outcomes of pregnant women in the third trimester who were infected by SARS-CoV-2 for the detection of the virus in the placenta and different samples of the newborn as well as detection of antibodies in the cord blood.

16 Feb 2022

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

A survey demonstrated that patients with systemic autoimmune rheumatic diseases commonly experience augmented disease severity and disrupted treatment regimens of disease-modifying antirheumatic drugs after acute COVID-19 course.

11 Feb 2022

New research confirms the safety of mRNA COVID-19 vaccines for people with cancer

New research in the February 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms that mRNA vaccine for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals.

10 Feb 2022

Philippines starts vaccinating children aged five to 11 against COVID-19

The Philippines began vaccinating children aged five to 11 against COVID-19 on Monday after initial hiccups over delayed deliveries of the Pfizer-BioNTech doses and opposition to the drive by some parents.

9 Feb 2022

Danish study of long COVID in teens

As an aftermath of the extended lockdowns and social distancing restrictions, Coronavirus disease 2019 (COVID-19) has impacted the quality of life of children and adolescents worldwide, not only physically due to the infection, but also mentally. A high level of anxiety and depression has been reported among pediatric patients and adolescents, many of whom were deprived of social interaction with peers during the pandemic.

9 Feb 2022

Headache News and Research

Latest Headache News and Research

Antibody levels against SARS-CoV-2 spike protein up to 12 months after COVID-19 infection in non-vaccinated individuals

Closing bars and restaurants does not appear to have suppressed COVID-19 in Japan

Prevalence of chemosensory loss induced by SARS-CoV-2 Omicron variant in Italy

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

Immunogenicity, efficacy, and safety of BNT162b2 or mRNA1273 fourth dose

Study determines 115 long COVID symptoms and their associated risk factors

Risk factors for COVID-19 in older adult patients with cancer

UC joins nationwide trial to evaluate efficacy of repurposed drugs for mild-to-moderate COVID-19

Pregnancy outcomes of pregnant women infected by SARS-CoV-2

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

New research confirms the safety of mRNA COVID-19 vaccines for people with cancer

Philippines starts vaccinating children aged five to 11 against COVID-19

Danish study of long COVID in teens

Impact of SARS-CoV-2 infection in pregnant women on maternal and perinatal outcomes

Paracetamol use increases blood pressure, study shows

Women, smokers and drinkers more likely to develop taste or smell disorders from COVID

Dizziness is a common symptom of COVID-19

Scientists identify genome regions linked to migraine risk

Relationship between SARS-CoV-2 neurotropism and Alzheimer's disease

Researchers discover mechanism behind loss of smell in people with COVID-19

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Headache News and Research

Latest Headache News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in